Carle Paul

38PUBLICATIONS
132CO-AUTHORS
PharmacogenomicsPharmaceutical delivery technologiesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Epigenetics (incl. genome methylation and epigenomics)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Aug 07, 2026
Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials.

|Mar 06, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.

April W Armstrong, Mark Lebwohl, Richard B Warren

|Jan 25, 2025
Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period.

Richard B Warren, Mark Lebwohl, Diamant Thaçi

|Jun 13, 2024
Gain-of-function human UNC93B1 variants cause systemic lupus erythematosus and chilblain lupus.

Clémence David, Carlos A Arango-Franco, Mihaly Badonyi

|Mar 06, 2024
Human neutrophils drive skin autoinflammation by releasing interleukin (IL)-26.

Alessia Baldo, Jeremy Di Domizio, Ahmad Yatim

|Jan 16, 2024
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.

Mark Lebwohl, Richard B Warren, Howard Sofen

Pageof 7

Frequent Collaborators

7 joint publications

Kristian Reich

7 joint publications

Cristina Bulai-Livideanu

6 joint publications

Richard B Warren

6 joint publications

Marie Tauber